Making CME Matter®
Managed Care Review Board - Analysis of Therapies for Growth Hormone Deficiency and Growth-Related Disorders Web Activity
Endocrinology
Curriculum:
The Managed Care Review Board™ – Analysis of Therapies for Growth Hormone Deficiency and Growth-Related Disorders
The Managed Care Review Board™ – Analysis of Therapies for Growth Hormone Deficiency and Growth-Related Disorders
Credits:
1.5 ACPE 1.5 ANCC Contact Hours 1.5 AMA PRA Category 1 Credit(s) ™
1.5 ACPE 1.5 ANCC Contact Hours 1.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
May 30, 2013
May 30, 2013
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Managed Care: Medical Directors, Pharmacists, Pharmacy Directors, Physicians, Registered Nurses
Relevant Terms:
Growth Hormone Deficiency, Growth Hormone Disorders, Growth Hormone Replacement Therapy, Managed Care, Recombinant Human Growth Hormone
Albert Tzeel, MD, MHSA, CPE, FACPE, FAAP
Albert Tzeel, MD, MHSA, CPE, FACPE, FAAP
Medical Director
HumanaOne
Milwaukee, Wisconsin
Bio
Albert Tzeel, MD, MHSA, CPE, FACPE, FAAP is the National Medical Director for HumanaOne, based in Milwaukee, Wisconsin. In his current role, Dr. Tzeel functions as a member of the executive management team for the Individual Health Insurance Product. He provides clinical input and expertise to the development, implementation and actions of underwriting as well as strategic marketing of healthier risks. In addition, Dr. Tzeel creates clinical strategies coordinated with other clinical management processes in place throughout the company. Specifically, he functions as the internal subject matter expert on the topic of diabetes. Prior to his assuming the role with HumanaOne, Dr. Tzeel was the Regional Market Medical Officer for Humana's Wisconsin and Michigan markets. He is a Board Certified pediatrician.
Dr. Tzeel joined Humana in March, 1999 as Medical Director for the Milwaukee market. Previously, he served as Associate Medical Director for the Health Alliance Plan in Detroit, Michigan. Dr. Tzeel earned his Medical Degree from the University of Michigan Medical School in Ann Arbor, MI and his Masters in Health Services Administration from the University of Michigan School of Public Health, also in Ann Arbor. He is a Certified Physician Executive, a Fellow of the American College of Physician Executives and a Fellow of the American Academy of Pediatrics.
Dr. Tzeel represents Humana on numerous external committees including the Board of Directors of the Center for Health Value Innovation (www.vbhealth.org) and the Board of Advisors for the Wisconsin Health Information Exchange (www.whie.org). He had also been appointed to the Governance Committee of the Wisconsin Relay of Electronic Data (WIRED) for Health Board. Earlier, he served as the Chair of the Healthcare subcommittee of the Wisconsin Partnership on Activity and Nutrition. Dr. Tzeel is the author or co-author of multiple papers and books including "When to Call the Doctor" (Dalmatian Press, 1999) and "The Encyclopedia of Children's Health and Wellness" (Facts on File, 2004).
Linda Bevington, RN, BSN, CPN
Linda Bevington, RN, BSN, CPN
Patient/Family Educator
Family Learning Center
Children's Hospital of Philadelphia
Philadelphia, PA
Bio
Linda Bevington, RN, BSN, CPN is a Patient Family Educator at Children's Hospital of Philadelphia (CHOP). She has over 15 years experience in training patients and caregivers to use various growth hormone therapy devices. Ms. Bevington has served as faculty on several continuing nursing and patient education programs and recently presented a poster at the 28th Annual Pediatric Nursing Conference on the use of video instruction to improve caregiver education. Along with her colleagues from CHOP's Artificial Airway Advisory Group, she received the Health Care Education Association's Award for Excellence in Practice: Patient/Community Education for her work to optimize education for caregivers with children with a tracheotomy and ventilator being discharged to home care.
Pinchas Cohen, MD
Pinchas Cohen, MD
Professor and Chief of Endocrinology
Mattel Children's Hospital
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
Bio
Dr. Cohen graduated with highest honors in 1986 from the Technion Medical School in Israel, and trained in Pediatrics, Endocrinology and Diabetes at Stanford University until 1992. He was an Associate Professor and Program Director at the University of Pennsylvania and Children's Hospital of Philadelphia until 1998. He is currently a Professor and Chief of Endocrinology at Mattel Children's Hospital, David Geffen School of Medicine at the University of California, Los Angeles (UCLA). He is also the associate director of the UCSD/UCLA Diabetes/Endocrinology Research Center. He was inducted into both the Society for Pediatric Research and the American Pediatric Society. He is the recipient of Juvenile Diabetes Association, American Diabetes Association, Pediatric Diabetes & Endocrinology Society, Eli Lilly, CaPCURE, and Ross awards, and most recently, the American Pediatric Society Best Science Award. Dr. Cohen published over 250 papers focusing on diabetes, growth disorders, cancer, aging, GH/IGF biology and the emerging science of humanin and other mitochondrial peptides. He received grants from the National Institutes of Health (NIH), FDA, and various foundations including the Prostate Cancer Foundation. He recently received a EUREKA-Award and the NIH-Director-Transformative RO1-Grant. He serves on several NIH study sections and his editorial services include being an associate editor of Pediatric Research and a member of the editorial boards of Journal of Clinical Endocrinology and Metabolism, Endocrinology, and the Journal of GH and IGF Research, as well as being an executive officer of the GH Research society, the IGF Society and the Endocrine Society Steering Committee.
Terri H. Lipman, PhD, CRNP, FAAN
Terri H. Lipman, PhD, CRNP, FAAN
Miriam Stirl Endowed Term Professor of Nutrition
Professor of Nursing of Children
University of Pennsylvania School of Nursing
Philadelphia, PA
Bio
Terri H. Lipman, PhD, CRNP, FAAN, is the Miriam Stirl Endowed Term Professor of Nutrition, a Professor of Pediatric Nursing at the University of Pennsylvania and the director of the Pediatric Acute/Chronic and Pediatric Oncology Nurse Practitioner Programs. She is a faculty member of the Center for Health Equities, associated faculty in the Center for Public Health Initiatives and a Distinguished Fellow in the Netter Center for Community Partnerships. She is the recipient of the Lindback Award for Distinguished Teaching. Dr. Lipman is also a pediatric nurse practitioner in the Division of Endocrinology and Diabetes at the Children's Hospital of Philadelphia.
Dr. Lipman received her BSN from Temple University in Philadelphia, and her MSN, PhD and CRNP from the University of Pennsylvania. After receiving her master's degree she practiced as an advanced practice nurse at St. Christopher's Hospital for Children. Dr. Lipman serves on numerous professional committees. She is the co-chair of the Surveillance Committee for the Pennsylvania Diabetes Action Plan and has long been active in the PENS organization. She has served as Research Chair, Grant Director and is currently the editor of the PENS column in the Journal of Pediatric Nursing.
Dr. Lipman has published widely and has given numerous national and international presentations. Her major areas of research have been the epidemiology of diabetes and assessment of growth of children. The Philadelphia Pediatric Diabetes Registry is one of only three longstanding such registries in the United States. She and Karen Hench, RN, MS, were co-principal investigators of a multicenter randomized, controlled trial evaluating growth assessment in primary care practices. That study, funded by the Genentech Foundation for Growth and Development and by PENS, was published in the Archives of Diseases in Childhood and the Journal of Pediatric Nursing and has received widespread coverage in the lay press. Dr. Lipman's current research interests include racial disparities in children with endocrine disorders, the effect of the economic distress on food choices in adolescents, and community based participatory research. Dr. Lipman's nurse practitioner students collaborated with inner city high school students to screen children in the community for diabetes risk factors. The students received a Mayoral Proclamation and Citations from Philadelphia City Council for their service to the community.
Dr. Lipman received her BSN from Temple University in Philadelphia, and her MSN, PhD and CRNP from the University of Pennsylvania. After receiving her master's degree she practiced as an advanced practice nurse at St. Christopher's Hospital for Children. Dr. Lipman serves on numerous professional committees. She is the co-chair of the Surveillance Committee for the Pennsylvania Diabetes Action Plan and has long been active in the PENS organization. She has served as Research Chair, Grant Director and is currently the editor of the PENS column in the Journal of Pediatric Nursing.
Dr. Lipman has published widely and has given numerous national and international presentations. Her major areas of research have been the epidemiology of diabetes and assessment of growth of children. The Philadelphia Pediatric Diabetes Registry is one of only three longstanding such registries in the United States. She and Karen Hench, RN, MS, were co-principal investigators of a multicenter randomized, controlled trial evaluating growth assessment in primary care practices. That study, funded by the Genentech Foundation for Growth and Development and by PENS, was published in the Archives of Diseases in Childhood and the Journal of Pediatric Nursing and has received widespread coverage in the lay press. Dr. Lipman's current research interests include racial disparities in children with endocrine disorders, the effect of the economic distress on food choices in adolescents, and community based participatory research. Dr. Lipman's nurse practitioner students collaborated with inner city high school students to screen children in the community for diabetes risk factors. The students received a Mayoral Proclamation and Citations from Philadelphia City Council for their service to the community.
Mark E. Molitch, MD
Mark E. Molitch, MD
Professor of Medicine
Endocrinology
Northwestern University Feinberg School of Medicine
Chicago, IL
Bio
Dr. Molitch is an endocrinologist specializing in diabetes at Northwestern Memorial Hospital. He is also a Professor of Medicine in the Division of Endocrinology, Metabolism, and Molecular Medicine at the Northwestern University's Feinberg School of Medicine. His specialties include pathogenesis and treatment of pituitary tumors as well as the treatment of diabetic complications. Before earning his doctorate from the University of Pennsylvania, Dr. Molitch completed a fellowship with the University of California-Los Angeles Medical Center. He is board certified in the areas of endocrinology, diabetes and metabolism and internal medicine. Dr. Molitch is also devoted to serving the underprivileged people of Bolivia as cofounder of a clinic called Centro Medico Humberto Parra.
In addition to editing eight books and journal volumes, Dr. Molitch has authored or coauthored more than 350 original papers, review articles, book chapters, case reports and other publications. For many years, Dr. Molitch was an Associate Editor of the Year Book of Endocrinology and is an Editor of the journal, Pituitary. In 1997, Dr. Molitch was named "Outstanding Physician Educator in the Field of Diabetes" by the American Diabetes Association. In 2006 he was elected to the Council of The Endocrine Society. He is currently Chair of the Clinical Endocrinology Update 2010 program committee of the Endocrine Society.
Nancy A. Nickman, PhD, RPh
Nancy A. Nickman, PhD, RPh
Professor of Pharmacotherapy
Department of Pharmacotherapy
University of Utah College of Pharmacy
Salt Lake City, UT
Bio
Dr. Nancy Nickman is a Professor of Pharmacotherapy and Presidential Teaching Scholar in the College of Pharmacy at the University of Utah. She received a Bachelor of Science in Pharmacy degree from the University of Montana and graduate degrees from the University of Minnesota in both Hospital Pharmacy (MS) and Social and Administrative Pharmacy (PhD). She also completed a two year ASHP Residency in Hospital Pharmacy at United and Children's Hospital in St. Paul, Minnesota (1982-1984). Nancy served as a tenured professor from 1987-2001, and returned to the faculty as a Professor of Pharmacotherapy in 2004 after owning her own business for five years. In 1995, she was named a University of Utah Presidential Teaching Scholar (award merged in 1997 with the University of Utah Distinguished Teaching Award). Her teaching and research expertise includes patient-centered outcomes research to improve provision and quality of patient care based on application of industrial engineering and economic analyses. Publications and presentations include work sampling evaluations of institutional pharmacy services for redesign of structural and functional activities, pre-post analyses of the impact of technology on the practice of health professionals, simulated time-and-motion evaluations coupled with microcost analyses of issues related to medication preparation and administration, and simulated time-and motion analysis of devices intended for medication self-administration.
| 1. | Assess the clinical and psychosocial implications caused by the effects of GHD and growth-related disorders | 2. | Implement clinical practice guidelines for GHD and growth-related disorders that ensure early and accurate diagnoses, testing requirements, coding, treatment considerations, and follow-up for optimal patient outcomes |
| 3. | Employ pharmacoeconomic modeling and other decision support tools to appropriately invest resources on GH replacement therapy | 4. | Provide accurate and appropriate counsel as part of the care team |
| 5. | Provide appropriate care and counsel for patients and their families |
| 1. | Assess the clinical and psychosocial implications caused by the effects of GHD and growth-related disorders |
| 2. | Implement clinical practice guidelines for GHD and growth-related disorders that ensure early and accurate diagnoses, testing requirements, coding, treatment considerations, and follow-up for optimal patient outcomes |
| 3. | Employ pharmacoeconomic modeling and other decision support tools to appropriately invest resources on GH replacement therapy |
| 4. | Provide accurate and appropriate counsel as part of the care team |
| 5. | Provide appropriate care and counsel for patients and their families |
Jointly sponsored/coprovided by the Postgraduate Institute for Medicine and Impact Education, LLC
www.impactedu.net www.pimed.com
The Managed Care Review Board™ – Analysis of Therapies for Growth Hormone Deficiency and Growth-Related Disorders
www.impactedu.net www.pimed.com
The Managed Care Review Board™ – Analysis of Therapies for Growth Hormone Deficiency and Growth-Related Disorders
Supported by an educational grant from Novo Nordisk, Inc.
Estimated time to complete activity: 1.5 hours
Target Audience
- Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
- Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for growth/growth disorders including: physicians, pharmacists, registered nurses, and case managers
Special Offering
Video demonstration of various recombinant human growth hormone (rhGH) administration devices by a nurse specialist. Statement of Need
The treatment of children with recombinant human growth hormone (rhGH) can be effective for increasing height toward normalization in all indications, particularly in children with growth hormone deficiency (GHD). Some studies have shown that children with idiopathic short stature (ISS) and GHD suffer from stress and other emotional and behavioral problems. Adults with GHD receiving rhGH therapy show improvements in body composition, quality of life, and surrogate markers for cardiovascular disease.
The treatment of GHD and growth-related disorders present distinct challenges for MCOs, payers, and affiliated providers. Balancing resource allocation with patient safety and optimal clinical outcome is paramount to payers and patients alike. Informed decisions are needed about the optimal role of GH replacement therapy so that patients who will benefit most are sure to receive it. This activity will address the educational needs of the target audience to enhance the health and well-being of many health plan patients, both children and adults, who suffer from GHD and growth-related disorders.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (1.5 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – 0809-9999-13-200-H01-P)
Type of Activity: Application
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.
Nursing Continuing Education
Credit Designation
This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.
Accreditation Statements
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
| Name of Faculty or Presenter | Reported Financial Relationship |
| Albert Tzeel, MD, MHSA, CPE, FACPE, FAAP | Consulting Fees: Amylin Pharmaceuticals Inc. |
| Linda Bevington, RN, BSN, CPN | No financial interest/relationships relating to the topic of this activity |
| Pinchas Cohen, MD | Consulting Fees: Novo Nordisk, Inc. |
| Terri H. Lipman, PhD, CRNP, FAAN | Consulting Fees: Roche, Inc. |
| Mark E. Molitch, MD | Consulting Fees: Novo Nordisk, Inc. Contracted Research: Novo Nordisk, Inc. and Eli Lilly and Company |
| Nancy A. Nickman, PhD, RPh | Contracted Research: Amgen Inc. and Novartis Pharmaceuticals Corporation |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
| Planner: Steven Casebeer, MBA | Has nothing to disclose. |
Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period May 30, 2013 through November 30, 2014, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the embedded questions within the activity; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.
Media
Internet
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Hardware/Software Requirements
Google Chrome for Windows, Mac, or Linux
Internet Explorer 7.0+ for Windows
Mozilla 1.4+ for Windows, Mac, or Linux
Firefox 3.5+ for Windows, Mac, or Linux
Safari 4.0+ for Mac
Fee Information
There is no fee for this educational activity.
If you have any questions, please call (215) 619-8812 or email MCRB@impactedu.net
Select button below to begin the activity.
© 2007-2024 HealthCourse, Inc. All rights reserved.
